

## **Gambro acquires clinics in the US**

Stockholm, Sweden, April 3, 2001 - Gambro AB (OM Stockholm Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that its wholly owned US subsidiary, Gambro Healthcare, Inc., has acquired substantially all of the dialysis-related assets owned by Renal Management, Inc. (RMI). These assets include 21 clinics that serve 950 patients in Louisiana, Nebraska, Iowa, Missouri and Kansas. Prior to this acquisition, RMI also held contracts to provide acute dialysis services to 16 hospitals and skilled nursing facilities whereby approximately 11,000 acute treatments are performed annually.

“We are very excited about adding Renal Management Inc. into the Gambro Healthcare family. This acquisition further demonstrates Gambro’s commitment to providing quality care for our patients and being among the world’s leaders in the industry. Also, we are pleased that Jo Ann Otts, Vice President of Operations for RMI, will join the Gambro team as a Regional Vice President of Operations and continue to manage the operations and development of the acquired clinics. This acquisition gives Gambro a greater presence within Louisiana, Nebraska, Iowa, Missouri and Kansas,” stated Larry Buckelew, President and CEO of Gambro Healthcare US. “Focus for Gambro Healthcare US in the immediate future remains on internal processes and leverage on the new organizational and management structure in order to improve both care and business quality. During this phase there will be fewer acquisitions than were implemented previously, and investments in new business opportunities will be made on highly selective criteria.”

Gambro now owns, operates, manages or provides consulting services to about 520 dialysis centers in the United States that serve over 39,000 patients across 33 states and the District of Columbia.

Gambro Healthcare is a leading provider of kidney dialysis services in the US. It is a fully integrated service provider of renal replacement therapy. Its activities include physician practice management, dialysis services, and clinical laboratory services.

For further information please contact:

Bengt Mod  r, Investor Relations, tel. +46-8-613 65 00, +46-733-66 65 33

Karin Avasalu, Corporate Communications, tel. +46-8-613 65 00, +46-70-513 65 99

Kevin Smith, President Gambro Inc., Investor Relations US, tel. +1-303 231 4750

*Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with about 47,000 patients in 600 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 22 billion (USD 2.4 billion), has approximately 18,000 employees in some 40 countries.*

**Gambro AB**

A public company (publ)  
Reg no. 556041-8005  
Hamngatan 2, P O Box 7373  
SE-103 91 Stockholm  
Sweden  
Tel +46 8-613 65 00  
Fax +46 8-611 28 30  
info@gambro.com  
www.gambro.com